iRadimed Corporation (NASDAQ:IRMD – Get Free Report) announced a quarterly dividend on Friday, May 1st. Shareholders of record on Friday, May 15th will be given a dividend of 0.20 per share by the medical equipment provider on Friday, May 29th. This represents a c) dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date is Friday, May 15th.
iRadimed has a dividend payout ratio of 40.2% indicating that its dividend is sufficiently covered by earnings. Equities research analysts expect iRadimed to earn $2.16 per share next year, which means the company should continue to be able to cover its $0.80 annual dividend with an expected future payout ratio of 37.0%.
iRadimed Stock Performance
Shares of IRMD stock traded up $3.71 on Friday, hitting $87.15. The company had a trading volume of 346,336 shares, compared to its average volume of 86,565. iRadimed has a twelve month low of $50.31 and a twelve month high of $107.90. The firm has a market cap of $1.11 billion, a P/E ratio of 49.80 and a beta of 1.11. The stock’s 50-day moving average is $96.69 and its two-hundred day moving average is $93.87.
Key iRadimed News
Here are the key news stories impacting iRadimed this week:
- Positive Sentiment: Q1 earnings and revenue beat consensus: iRadimed reported non?GAAP EPS of $0.49 (GAAP $0.45) and revenue of ~$22.0M, both above expectations, with year?over?year EPS and revenue growth — a primary driver of the intraday rally. iRadimed (IRMD) Beats Q1 Earnings and Revenue Estimates
- Positive Sentiment: Record GAAP and improved margins: management highlighted record GAAP diluted EPS and improved net margin/ROE metrics, signaling operating leverage and pricing/volume strength. IRADIMED Reports First Quarter 2026 Financial Results
- Positive Sentiment: Dividend increase maintained: the company announced a regular quarterly cash dividend of $0.20 (up from $0.17), which supports income-oriented investors and signals confidence in cash flow. IRADIMED Reports First Quarter 2026 Financial Results
- Neutral Sentiment: Full?year guidance reaffirmed and nudged slightly above consensus: FY2026 EPS guidance was set to $2.06–$2.21 (consensus ~2.05), and revenue guidance roughly $91–96M (consensus ~$92.4M) — supportive but not a major beat. IRADIMED Reports First Quarter 2026 Financial Results
- Neutral Sentiment: CEO insider sale disclosed: CEO Roger Susi sold 3,750 shares under a pre?arranged Rule 10b5?1 plan — a small, orderly sale that management says was planned, so likely neutral for most investors. Insider Selling: iRadimed CEO Sells Shares
- Negative Sentiment: Q2 revenue and mid?point EPS guidance slightly cautious vs. street: Q2 revenue guidance of $20.0–$21.0M is modestly below consensus (~$21.1M) and Q2 EPS guidance (0.44–0.48) straddles the street estimate — this introduces short?term execution risk that could temper gains. IRADIMED Reports First Quarter 2026 Financial Results
iRadimed Company Profile
iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.
In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.
Further Reading
Receive News & Ratings for iRadimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iRadimed and related companies with MarketBeat.com's FREE daily email newsletter.
